01 / CURRENT PRODUCTS
9 current products across 19 dose and supply variants. Available inventory leads the catalog. Products without a current stock position remain open for demand inquiries. No payment is taken here.
09 PRODUCTS
Live inventory is being verified.
An investigational triple-receptor agonist peptide. Human phase 2 data has been published. It is not a component of any FDA-approved drug.
EVIDENCEEvidence grade B: Human evidenceView record →A dual GIP/GLP-1 receptor agonist peptide. The active ingredient appears in an FDA-approved product, which establishes that the molecule is well characterised — it says nothing about any individual third-party vial.
EVIDENCEEvidence grade A: Approved comparator existsView record →A named BPC-157/TB-500 blend in the current MONARCH HEALTH LABS catalog. Its component ratio is confirmed with the written response.
EVIDENCEEvidence grade U: Identity insufficiently definedView record →A named blend in the current MONARCH HEALTH LABS catalog. Its full component list and ratios are confirmed with the written response.
EVIDENCEEvidence grade U: Identity insufficiently definedView record →Cobalamin exists in several forms — cyanocobalamin, methylcobalamin, hydroxocobalamin — which are not interchangeable for identity purposes.
EVIDENCEEvidence grade U: Identity insufficiently definedView record →A tripeptide corresponding to the C-terminal fragment of alpha-MSH. Evidence located is preclinical.
EVIDENCEEvidence grade C: Preclinical evidenceView record →A ubiquitous redox cofactor. Direct intravenous human research is limited in scope.
EVIDENCEEvidence grade B: Human evidenceView record →A synthetic fragment of human growth hormone. The published record is preclinical and metabolic in nature.
EVIDENCEEvidence grade C: Preclinical evidenceView record →A 29-amino-acid GHRH analog. A product containing sermorelin acetate held FDA approval historically.
EVIDENCEEvidence grade A: Approved comparator existsView record →No products match these filters.